

**Table 4.10.2: Recommended use of 4vMenCV by age group for persons with medical condition(s) associated with an increased risk of meningococcal disease**

Age at commencement of vaccine course	Recommended brand	Primary immunisation	Recommended interval between primary doses*	Timing of booster doses
2–6 months	Menveo	3 doses	8 weeks	At age 12–18 months, then 3 years later, then every 5 years thereafter
7–11 months	Menveo	2 doses	12 weeks	3 years after the primary doses, then every 5 years thereafter
12–23 months	Menveo or Nimenrix	2 doses	12 weeks	3 years after the primary doses, then every 5 years thereafter
2–6 years	Menactra, Menveo or Nimenrix	2 doses	8 weeks	3 years after the primary doses, then every 5 years thereafter
≥7 years	Menactra, Menveo or Nimenrix	2 doses	8 weeks	Every 5 years after the previous dose

\* Refer to Table 2.1.7 *Minimum acceptable dose intervals for children <10 years of age* for advice on minimum intervals.